Cornerstone Advisors (Washington)’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-239	Closed	-$1K	–	826
2020 Q1	$1K	Hold	239	–	–	﹤0.01%	754
2019 Q4	$1K	Hold	239	–	–	﹤0.01%	753
2019 Q3	$1K	Hold	239	–	–	﹤0.01%	744
2019 Q2	$1K	Buy	+239	New	+$1.15K	﹤0.01%	1472

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Cornerstone Advisors (Washington)'s PGNX Position: Q2 2020 in Review

Cornerstone Advisors (Washington) sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 239 shares — an estimated $1K sold.

Cornerstone Advisors (Washington) first reported a position in PGNX in Q2 2019 and held it in 4 quarters. The position peaked at $1K in Q1 2020. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Cornerstone Advisors (Washington) reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Cornerstone Advisors (Washington) sold 239 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $1K.
Cornerstone Advisors (Washington) first reported a position in Progenics Pharmaceuticals Inc in Q2 2019 and held it in 4 quarters.
Cornerstone Advisors (Washington)'s Progenics Pharmaceuticals Inc position peaked at $1K in Q1 2020.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q2 2020, filed 29 Jul 2020.